NO20043866L - Farmasoytisk formulering av IRESSA omfattende et vannopploselig cellulosederivat - Google Patents

Farmasoytisk formulering av IRESSA omfattende et vannopploselig cellulosederivat

Info

Publication number
NO20043866L
NO20043866L NO20043866A NO20043866A NO20043866L NO 20043866 L NO20043866 L NO 20043866L NO 20043866 A NO20043866 A NO 20043866A NO 20043866 A NO20043866 A NO 20043866A NO 20043866 L NO20043866 L NO 20043866L
Authority
NO
Norway
Prior art keywords
iressa
water
pharmaceutical formulation
cellulose derivative
soluble cellulose
Prior art date
Application number
NO20043866A
Other languages
English (en)
Other versions
NO328658B1 (no
Inventor
Paul Richard Gellert
Michael Davis Parker
Marcel De Matas
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27767732&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20043866(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0204392A external-priority patent/GB0204392D0/en
Priority claimed from GB0212462A external-priority patent/GB0212462D0/en
Priority claimed from GB0213267A external-priority patent/GB0213267D0/en
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of NO20043866L publication Critical patent/NO20043866L/no
Publication of NO328658B1 publication Critical patent/NO328658B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO20043866A 2002-02-26 2004-09-15 Farmasoytisk formulering av IRESSA omfattende et vannopploselig cellulosederivat, fremstilling av slike samt anvendelse av slike NO328658B1 (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0204392A GB0204392D0 (en) 2002-02-26 2002-02-26 Pharmaceutical compound
GB0212462A GB0212462D0 (en) 2002-05-30 2002-05-30 Pharmaceutical compound
GB0213267A GB0213267D0 (en) 2002-06-11 2002-06-11 Pharmaceutical composition
PCT/GB2003/000803 WO2003072139A1 (en) 2002-02-26 2003-02-24 Pharmaceutical formulation of iressa comprising a water-soluble cellulose derivative

Publications (2)

Publication Number Publication Date
NO20043866L true NO20043866L (no) 2004-09-15
NO328658B1 NO328658B1 (no) 2010-04-19

Family

ID=27767732

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20043866A NO328658B1 (no) 2002-02-26 2004-09-15 Farmasoytisk formulering av IRESSA omfattende et vannopploselig cellulosederivat, fremstilling av slike samt anvendelse av slike

Country Status (30)

Country Link
US (2) US20050163835A1 (no)
EP (1) EP1480679B1 (no)
JP (1) JP4544863B2 (no)
KR (2) KR20100090726A (no)
CN (1) CN1326569C (no)
AR (1) AR038848A1 (no)
AT (1) ATE362771T1 (no)
AU (1) AU2003208444B2 (no)
BR (1) BRPI0307786B8 (no)
CA (1) CA2476587C (no)
CO (1) CO5601038A2 (no)
CY (1) CY1108026T1 (no)
DE (1) DE60313956T2 (no)
DK (1) DK1480679T3 (no)
ES (1) ES2286406T3 (no)
HK (1) HK1070585A1 (no)
IL (2) IL163642A0 (no)
IS (1) IS2462B (no)
MX (1) MXPA04008307A (no)
MY (1) MY135609A (no)
NO (1) NO328658B1 (no)
NZ (1) NZ534513A (no)
PL (1) PL208114B1 (no)
PT (1) PT1480679E (no)
RU (1) RU2318518C2 (no)
SA (1) SA03240043B1 (no)
TW (1) TWI271193B (no)
UA (1) UA76325C2 (no)
UY (1) UY27682A1 (no)
WO (1) WO2003072139A1 (no)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2477350C (en) 2002-02-26 2013-02-12 Astrazeneca Ab Novel crystalline forms of the anti-cancer compound zd1839
GB0317663D0 (en) * 2003-07-29 2003-09-03 Astrazeneca Ab Pharmaceutical composition
SI1746999T1 (sl) 2004-05-06 2012-01-31 Warner Lambert Co 4-fenilamino-kinazolin-6-il-amidi
WO2007031933A2 (en) 2005-09-12 2007-03-22 Actelion Pharmaceuticals Ltd Stable pharmaceutical composition comprising a pyrimidine-sulfamide
CA2667167C (en) * 2006-10-27 2014-02-18 Pfizer Products Inc. Hydroxypropyl methyl cellulose hard capsules and process of manufacture
BRPI0812064B8 (pt) * 2007-06-06 2021-05-25 Basf Se formulação farmacêutica na forma de aglomerados, comprimidos, e, processo para a produção de uma formulação farmacêutica
MX2010001837A (es) 2007-08-17 2010-03-10 Actelion Pharmaceuticals Ltd Derivados de 4-pirimidinasulfamida.
US8728516B2 (en) * 2009-04-30 2014-05-20 Abbvie Inc. Stabilized lipid formulation of apoptosis promoter
TWI532484B (zh) * 2009-06-08 2016-05-11 艾伯維有限公司 包含凋亡促進劑之固態分散劑
TWI471321B (zh) * 2009-06-08 2015-02-01 Abbott Gmbh & Co Kg Ｂｃｌ－２族群抑制劑之口服醫藥劑型
MX2012000048A (es) * 2009-07-02 2012-01-27 Wyeth Llc Formulaciones de comprimidos de 3-cianoquinolina y usos de los mismos.
WO2011079127A1 (en) * 2009-12-22 2011-06-30 Abbott Laboratories Abt-263 capsule
JP4574742B1 (ja) * 2010-04-08 2010-11-04 有限会社ミールジャパン プロポリス組成物
UA113500C2 (xx) 2010-10-29 2017-02-10 Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб
BR112013009093B1 (pt) 2010-10-29 2022-04-19 Abbvie Inc Processo para a preparação de uma dispersão sólida contendo um agente indutor de apoptose
US8395552B2 (en) 2010-11-23 2013-03-12 Metamagnetics, Inc. Antenna module having reduced size, high gain, and increased power efficiency
US8722657B2 (en) 2010-11-23 2014-05-13 Abbvie Inc. Salts and crystalline forms of an apoptosis-inducing agent
KR20190109590A (ko) 2010-11-23 2019-09-25 애브비 아일랜드 언리미티드 컴퍼니 선택적인 ｂｃｌ­２ 억제제를 사용하는 치료 방법
CN102631347B (zh) * 2012-05-03 2014-06-25 石药集团中奇制药技术（石家庄）有限公司 一种吉非替尼药物组合物及其制备方法
US20140275082A1 (en) 2013-03-14 2014-09-18 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
KR101332829B1 (ko) * 2013-05-31 2013-11-27 재단법인 통합의료진흥원 보중익기탕을 포함하는 폐암 치료용 조성물
GB201400034D0 (en) 2014-01-02 2014-02-19 Astrazeneca Ab Pharmaceutical Compositions comprising AZD9291
KR101721831B1 (ko) * 2014-11-06 2017-03-31 주식회사 종근당 로베글리타존을 함유하는 경구 투여용 약제학적 조성물
WO2016096999A1 (en) 2014-12-19 2016-06-23 Synthon B.V. Pharmaceutical composition comprising gefifinib
PT3263110T (pt) * 2015-02-26 2023-08-01 Takeda Pharmaceuticals Co Comprimido compreendendo um derivado de metoxiureia e partículas de manitol
KR101739731B1 (ko) * 2015-12-31 2017-05-25 환인제약 주식회사 유당불내성 환자에게 투여가 가능하며, 복용편의성이 향상된 게피티니브를 함유하는 약제학적 조성물
CN108096251B (zh) * 2016-11-24 2021-11-16 江苏恒瑞医药股份有限公司 一种吉非替尼药物组合物及其制备方法
CN107007562B (zh) * 2017-02-16 2020-10-27 南京优科制药有限公司 一种吉非替尼片剂及其制备方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3608063A (en) * 1969-08-15 1971-09-21 Gilbert S Banker Molecular drug entrapment process and compositions
US4178376A (en) * 1977-01-21 1979-12-11 Interx Research Corporation Method for inducing rapid therapeutically effective antimalarial levels of certain selected conventional antimalarials
US4344934A (en) * 1978-11-20 1982-08-17 American Home Products Corporation Therapeutic compositions with enhanced bioavailability
US4704284A (en) * 1982-08-12 1987-11-03 Pfizer Inc. Long-acting matrix tablet formulations
GB9300059D0 (en) * 1992-01-20 1993-03-03 Zeneca Ltd Quinazoline derivatives
GB9207988D0 (en) * 1992-04-10 1992-05-27 Smithkline Beecham Plc Topical composition
AU680019B2 (en) * 1993-08-30 1997-07-17 Warner-Lambert Company Llc Tablet coating based on a melt-spun mixture of a saccharide and apolymer
US5559158A (en) * 1993-10-01 1996-09-24 Abbott Laboratories Pharmaceutical composition
GB9508538D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
GB2306885B (en) * 1995-11-08 1999-07-14 Reckitt & Colmann Prod Ltd Supersaturated Pharmaceutical Compositions
ATE554750T1 (de) * 1997-03-05 2012-05-15 Sugen Inc Hydrophobe pharmazeutische wirkstoffe enthaltende zubereitungen
PT901786E (pt) * 1997-08-11 2007-08-07 Pfizer Prod Inc Disperções farmacêuticas sólidas com biodisponibilidade melhorada
UA74141C2 (uk) * 1998-12-09 2005-11-15 Дж.Д. Сірл Енд Ко. Фармацевтична композиція на основі тонкоподрібненого еплеренону (варіанти), спосіб її одержання та спосіб лікування розладів, опосередкованих альдостероном (варіанти)
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6294192B1 (en) * 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
DE19911509A1 (de) * 1999-03-15 2000-09-21 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
US6383471B1 (en) * 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
ATE329579T1 (de) * 1999-11-12 2006-07-15 Abbott Lab Feste dispersion mit ritonavir, fenofibrat oder griseofulvin
US6287599B1 (en) * 2000-12-20 2001-09-11 Shire Laboratories, Inc. Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles
KR100397792B1 (ko) * 2001-06-28 2003-09-13 한국과학기술연구원 4-(페닐아미노)-[1,4]디옥사노[2,3-ｇ]퀴나졸린 유도체 및그의 제조방법
CA2477350C (en) * 2002-02-26 2013-02-12 Astrazeneca Ab Novel crystalline forms of the anti-cancer compound zd1839
KR20050104152A (ko) 2004-04-28 2005-11-02 최승호 경구용 약물의 흡수를 증진하는 약제학적 조성물

Also Published As

Publication number Publication date
US20090186890A1 (en) 2009-07-23
KR20040088524A (ko) 2004-10-16
IS2462B (is) 2008-11-15
DK1480679T3 (da) 2007-09-03
CN1326569C (zh) 2007-07-18
SA03240043B1 (ar) 2007-05-06
EP1480679B1 (en) 2007-05-23
BRPI0307786B8 (pt) 2021-05-25
UA76325C2 (uk) 2006-07-17
CY1108026T1 (el) 2013-09-04
TW200304379A (en) 2003-10-01
MY135609A (en) 2008-05-30
AR038848A1 (es) 2005-01-26
TWI271193B (en) 2007-01-21
CO5601038A2 (es) 2006-01-31
NO328658B1 (no) 2010-04-19
CA2476587C (en) 2010-05-04
WO2003072139A1 (en) 2003-09-04
AU2003208444A1 (en) 2003-09-09
KR20100090726A (ko) 2010-08-16
RU2004129280A (ru) 2005-06-10
DE60313956D1 (de) 2007-07-05
IS7420A (is) 2004-08-24
CN1638805A (zh) 2005-07-13
BR0307786A (pt) 2004-12-07
JP2005523293A (ja) 2005-08-04
IL163642A (en) 2007-07-24
PT1480679E (pt) 2007-07-18
JP4544863B2 (ja) 2010-09-15
US20050163835A1 (en) 2005-07-28
ATE362771T1 (de) 2007-06-15
UY27682A1 (es) 2003-10-31
NZ534513A (en) 2007-04-27
AU2003208444B2 (en) 2006-10-26
DE60313956T2 (de) 2008-05-15
CA2476587A1 (en) 2003-09-04
BRPI0307786B1 (pt) 2018-03-13
RU2318518C2 (ru) 2008-03-10
HK1070585A1 (en) 2005-06-24
ES2286406T3 (es) 2007-12-01
EP1480679A1 (en) 2004-12-01
IL163642A0 (en) 2005-12-18
PL372215A1 (en) 2005-07-11
PL208114B1 (pl) 2011-03-31
MXPA04008307A (es) 2004-11-26
KR101002374B1 (ko) 2010-12-17

Similar Documents

Publication Publication Date Title
NO20043866L (no) Farmasoytisk formulering av IRESSA omfattende et vannopploselig cellulosederivat
CY2017048I1 (el) Νεες φαρμακευτικες χρησεις των παραγωγων σταυροσπορινης
NO20042842L (no) Farmasoytiske formuleringer av platina-derivat
ATE336264T1 (de) Dispergierbare pharmazeutische zusammensetzungen
ATE337793T1 (de) Dispergierbare pharmazeutische zusammensetzung eines entzündungshemmers
TWI349664B (en) Benzimidazole derivatives: preparation and pharmaceutical applications
CY2018005I2 (el) Απο του στοματος φαρμακοτεχνικες μορφες της κλαντριβινης
NO20033384D0 (no) Farmasöytisk formulering
DK1545467T3 (da) Faste farmaceutiske formuleringer omfattende telmisartan
NO20033343L (no) Farmasöytiske doseringsformer av epothiloner for oral administrasjon
NO20033785D0 (no) Farmasöytisk formulering
NO20035438L (no) Farmasoytisk formulering for effektiv administrering av apomorfin, 6aR-(-)-N-propyl-norapomorfin og deres derivater og prodrugs derav
NO20035627D0 (no) Farmasöytisk formulering
FR2852845B1 (fr) Compositions pharmaceutiques a activite antibiotique
DE60336999D1 (de) Melatonin enthaltende pharmazeutische formulierung
PL1673349T3 (pl) Pochodne benzimidazolu: wytwarzanie i zastosowania farmaceutyczne
SI1480679T1 (sl) Farmacevtska formulacija Iressa, ki obsega vodotopen celulozni derivat
CL2003002295A1 (es) Derivados de bencenosulfonil-carbamoil-gamma-aminopropil sustituidos de 9-deoxo-9-dihidro-9a-aza-9a-homoeritromicina a y 5-o-desosaminil-9-deoxo-9-dihidro-9a-aza-9a-homoeritronolida a, composicion farmaceutica, procedimiento de preparacion, utiles pa
AU2003215543A1 (en) Water- soluble derivatives of lipophilic drugs
DK1467737T3 (da) Oralt dispergerbar farmaceutisk sammensætning indeholdende piribedil
FI20011809A0 (fi) Menetelmä polysakkaridijohdannaisen valmistamiseksi ja polysakkaridijohdannainen
NO20041236L (no) Farmasoytisk formulering
SE0201660D0 (sv) Pharmaceutical formulation
SE0200449D0 (sv) Pharmaceutical formulation
SE0103565D0 (sv) Pharmaceutical formulation

Legal Events

Date Code Title Description
MK1K Patent expired